Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bisphosphonate Osteonecrosis May Be Class Effect, FDA Safety Review Says

This article was originally published in The Pink Sheet Daily

Executive Summary

ODS review finds 139 cases of osteonecrosis in patients receiving IV bisphosphonates Zometa and Aredia, or oral drugs Fosamax and Actonel, although many fewer are found with oral drugs vs. IV. Zometa and Aredia are subject of March 4 oncologic drugs advisory committee meeting on osteonecrosis of the jaw.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts